Skip to main content
. 2023 Jul 19;12(3):213–222. doi: 10.12997/jla.2023.12.3.213

Fig. 1. Comparison between GLP-1 RA and the GLP-1/GIP dual agonist (tirzepatide).

Fig. 1

GLP-1, glucagon-like peptide-1; GIP, glucose-dependent insulinotropic polypeptide; RA, receptor agonist; HbA1c, glycated hemoglobin; GI, gastrointestinal; MACE, major adverse cardiovascular event.